Pesquisas alternativas:
level theory » model theory (Expandir a Pesquisa), cell theory (Expandir a Pesquisa)
doses devel » doses seven (Expandir a Pesquisa), doses derived (Expandir a Pesquisa), doses devoid (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
level ther » level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa), level three (Expandir a Pesquisa)
dose level » dose levels (Expandir a Pesquisa), noise level (Expandir a Pesquisa), dose live (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
de level » de leval (Expandir a Pesquisa), de leve (Expandir a Pesquisa), de leves (Expandir a Pesquisa)
drug de » drug dna (Expandir a Pesquisa)
level theory » model theory (Expandir a Pesquisa), cell theory (Expandir a Pesquisa)
doses devel » doses seven (Expandir a Pesquisa), doses derived (Expandir a Pesquisa), doses devoid (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa), develop them (Expandir a Pesquisa)
level ther » level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa), level three (Expandir a Pesquisa)
dose level » dose levels (Expandir a Pesquisa), noise level (Expandir a Pesquisa), dose live (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
de level » de leval (Expandir a Pesquisa), de leve (Expandir a Pesquisa), de leves (Expandir a Pesquisa)
drug de » drug dna (Expandir a Pesquisa)
41
Por Pereira, Edna F. R., Aracava, Yasco, DeTolla, Louis J., Beecham, E. Jeffrey, Basinger, G. William, Wakayama, Edgar J., Albuquerque, Edson X.
Publicado em 2014
“..., have low levels of circulating carboxylesterases—the enzymes that metabolize and inactivate OP...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
42
Por Yuan, Yong-Liang, Guo, Chang-Run, Cui, Ling-Ling, Ruan, Shi-Xia, Zhang, Chun-Feng, Ji, De, Yang, Zhong-Lin, Li, Fei
Publicado no Drug Des Devel Ther (2015)
“...BACKGROUND: Many synthesized drugs with clinical severe side effects have been used for diabetic...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
43
Por Ailawadhi, Sikander, Akard, Luke P., Miller, Carole B., Jillella, Anand, DeAngelo, Daniel J., Ericson, Solveig G., Lin, Felice, Warsi, Ghulam, Radich, Jerald
Publicado no Ther Adv Hematol (2016)
“.../2 and manageable with dose interruptions. A total of three patients experienced serious study drug...”Publicado no Ther Adv Hematol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
44
Por Tyler, Paul M., Servos, Mariah M., de Vries, Romy C., Klebanov, Boris, Kashyap, Trinayan, Sacham, Sharon, Landesman, Yosef, Dougan, Michael, Dougan, Stephanie K.
Publicado no Mol Cancer Ther (2017)
“... activation but clinically relevant once and twice weekly dosing schedules that incorporate sufficient drug...”Publicado no Mol Cancer Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
45
Por De Miranda, Briana R., Miller, James A., Hansen, Ryan J., Lunghofer, Paul J., Safe, Stephen, Gustafson, Daniel L., Colagiovanni, Dorothy, Tjalkens, Ronald B.
Publicado no J Pharmacol Exp Ther (2013)
“...There are currently no registered drugs that slow the progression of neurodegenerative diseases...”Publicado no J Pharmacol Exp Ther (2013)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
46
Por Lee, Jieon, Yoon, Seonghae, Shin, Donghoon, Han, HyeKyung, An, Hyungmi, Lee, Jongtae, Lim, Kyoung Soo, Yu, Kyung-Sang, Lee, Howard
Publicado em 2014
“... nomograms may be required in patients with IE, particularly for once-daily dosing. Therapeutic drug...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
47
“... the administration of different drugs together to create the anesthetic state. Anesthesiologists developed...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
48
Por Wang, Hui, Zhang, Xiang, He, Ji-Ye, Zheng, Xin-Feng, Li, De, Li, Zheng, Zhu, Jun-Feng, Shen, Chao, Cai, Gui-Quan, Chen, Xiao-Dong
Publicado no Arthritis Res Ther (2015)
“... patients with femoral neck fracture. Levels of SP, CGRP and inflammatory cytokines in synovium and synovial...”Publicado no Arthritis Res Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
49
Por Gavazzoni, Mara, Gorga, Elio, Derosa, Giuseppe, Maffioli, Pamela, Metra, Marco, Raddino, Riccardo
Publicado no Drug Des Devel Ther (2017)
“...BACKGROUND AND AIM: Clinical benefits of early high-dose statin therapy after acute coronary...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
50
Por DeRosa, F, Guild, B, Karve, S, Smith, L, Love, K, Dorkin, J R, Kauffman, K J, Zhang, J, Yahalom, B, Anderson, D G, Heartlein, M W
Publicado no Gene Ther (2016)
“... (hEPO) or factor IX (hFIX) protein. Dose-dependent protein production was observed for each mRNA...”Publicado no Gene Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
51
Por Barbarash, Olga, Gruzdeva, Olga, Uchasova, Evgenya, Belik, Ekaterina, Dyleva, Yulia, Karetnikova, Victoria
Publicado no Drug Des Devel Ther (2015)
“..., resulted in a decrease in free fatty acid levels. The positive effect of low-dose atorvastatin (20 mg/day...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
52
Por Chávez-López, María de Guadalupe, Zúñiga-García, Violeta, Hernández-Gallegos, Elisabeth, Vera, Eunice, Chasiquiza-Anchatuña, Carmen Alexandra, Viteri-Yánez, Marco, Sanchez-Ramos, Janet, Garrido, Efraín, Camacho, Javier
Publicado no Onco Targets Ther (2017)
“... apoptosis roughly four times in comparison to the effect of the drugs alone. Eag1 mRNA levels and protein...”Publicado no Onco Targets Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
53
Por Saltzstein, Daniel, Shore, Neal D., Moul, Judd W., Chu, Franklin, Concepcion, Raoul, de la Motte, Stephan, McLane, John A., Atkinson, Stuart, Yang, Alex, Crawford, E. David
Publicado no Ther Adv Urol (2017)
“... demonstrated a longer duration of LH suppression, with median levels remaining below 1.0 IU/l through Day 56...”Publicado no Ther Adv Urol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
54
Por Juarez, Maria, McGettrick, Helen M., Scheel-Toellner, Dagmar, Yeo, Lorraine, Spengler, Julia, de Paz, Banesa, Hardy, Rowan, Cooper, Mark, Raza, Karim, Buckley, Christopher D., Filer, Andrew
Publicado no Arthritis Res Ther (2016)
“...: Fibroblasts were isolated from the disease-modifying anti-rheumatic drug–naive Birmingham early arthritis...”Publicado no Arthritis Res Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
55
Por Kim, Yo Han, Choi, Hee Youn, Noh, Yook-Hwan, Lee, Shi Hyang, Lim, Hyeong-Seok, Kim, Chin, Bae, Kyun-Seop
Publicado no Drug Des Devel Ther (2015)
“... and high blood pressure. The aim of this study was to investigate the dose proportionality...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
56
Por Voors, Adriaan A., van de Wal, Ruud M., L Hartog, Jasper W., Vijn, Richard G., Hummel, Yoran M., Plokker, Thijs W. M., van Veldhuisen, Dirk J., Jaarsma, Wybren
Publicado em 2010
“... = −0.06; p = 0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
57
Por Erturk, Ayse, Adnan Akdogan, Remzi, Parlak, Emine, Cure, Erkan, Cumhur Cure, Medine, Ozturk, Cinar
Publicado em 2014
“... transaminase (ALT) normalization at the end of 4 years. CONCLUSION: Increasing ETV dose from 0.5 mg to 1 mg...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
58
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
59
Por Sahdev, Anil K., Raj, Vinit, Singh, Ashok K., Rai, Amit, Keshari, Amit K., De, Arnab, Samanta, Amalesh, Kumar, Umesh, Rawat, Atul, Kumar, Dinesh, Nath, Sneha, Prakash, Anand, Saha, Sudipta
Publicado no Cancer Biol Ther (2017)
“... was administered orally at 2 doses of 10 and 25 mg/kg daily for 15 d to observe the antiproliferative effect...”Publicado no Cancer Biol Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
60
Por Min, Jee Sun, Kim, Doyun, Park, Jung Bae, Heo, Hyunjin, Bae, Soo Hyeon, Seo, Jae Hong, Oh, Euichaul, Bae, Soo Kyung
Publicado no Drug Des Devel Ther (2016)
“...BACKGROUND: Evaluating the potential risk of metabolic drug–drug interactions (DDIs) is clinically...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo